- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1409EUR$1,600USD£1,239GBP
€1762EUR$2,000USD£1,548GBP
- Report
- December 2025
- 391 Pages
Global
From €5152EUR$5,850USD£4,529GBP
- Report
- February 2025
- 200 Pages
Global
From €3955EUR$4,490USD£3,476GBP
- Report
- December 2025
- 266 Pages
Global
From €5152EUR$5,850USD£4,529GBP
- Report
- January 2025
- 183 Pages
Global
From €3963EUR$4,500USD£3,484GBP
- Report
- September 2025
- 144 Pages
Global
From €2245EUR$2,549USD£1,974GBP
€2641EUR$2,999USD£2,322GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1057EUR$1,200USD£929GBP
€1321EUR$1,500USD£1,161GBP
- Report
- July 2025
- 215 Pages
Global
From €4399EUR$4,995USD£3,867GBP
- Report
- October 2025
- 160 Pages
Global
From €2957EUR$3,358USD£2,599GBP
€3479EUR$3,950USD£3,058GBP
- Report
- October 2025
- 160 Pages
Global
From €2957EUR$3,358USD£2,599GBP
€3479EUR$3,950USD£3,058GBP
- Report
- August 2025
- 150 Pages
Global
From €2957EUR$3,358USD£2,599GBP
€3479EUR$3,950USD£3,058GBP
- Report
- March 2025
- 150 Pages
Global
From €3391EUR$3,850USD£2,981GBP
€4272EUR$4,850USD£3,755GBP
- Report
- October 2025
- 83 Pages
Global
From €4272EUR$4,850USD£3,755GBP
- Report
- July 2025
- 100 Pages
United States
From €5240EUR$5,950USD£4,606GBP
- Report
- January 2023
- 388 Pages
Global
From €4651EUR$5,465USD£3,950GBP
- Report
- March 2024
- 80 Pages
Europe
From €5240EUR$5,950USD£4,606GBP
- Report
- September 2023
- 236 Pages
Global
From €5240EUR$5,950USD£4,606GBP
- Report
- July 2024
- 100 Pages
Global
From €2642EUR$3,000USD£2,323GBP
€3303EUR$3,750USD£2,903GBP
- Report
- June 2024
- 200 Pages
Global
From €5602EUR$6,360USD£4,924GBP
€7002EUR$7,950USD£6,155GBP
- Report
- February 2024
- 111 Pages
Global
From €4184EUR$4,750USD£3,677GBP

The Carbapenem market is a subset of the Antibiotics market, which is composed of drugs used to treat bacterial infections. Carbapenems are a class of antibiotics that are used to treat serious infections caused by bacteria that are resistant to other antibiotics. They are typically used as a last resort when other antibiotics have failed. Carbapenems are generally well-tolerated and have a low risk of side effects.
Carbapenems are used to treat a wide range of infections, including pneumonia, urinary tract infections, and skin and soft tissue infections. They are also used to treat infections caused by multidrug-resistant bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA).
The Carbapenem market is highly competitive, with several major players. These include Merck & Co., Pfizer, GlaxoSmithKline, AstraZeneca, and Sanofi. Other companies in the market include Allergan, Novartis, and Daiichi Sankyo. Show Less Read more